China Pharma Holdings Sees Increased Revenue From Sales Of Generic Version Of Bayer’s Aleve-D
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China Pharma Holdings reported a 39 percent increase in net income to $17.8 million in 2008 due to a 76.6 percent increase in sales of its leading OTC cold and flu product PuSen OK (naprooxen and pseudophedrine), the only generic version in China of Bayer's Aleve-D
You may also be interested in...
China Pharma Reports Slightly Higher Q2 Profits, Expects To Launch Generic Version Of AstraZeneca's Crestor In 2010
SHANGHAI - China Pharma Holdings, a generic drug provider in China, reported that its net income inched up by 6.2 percent to $4.3 million in the second quarter of 2009 compared with the same period of 2008
China Pharma Reports Slightly Higher Q2 Profits, Expects To Launch Generic Version Of AstraZeneca's Crestor In 2010
SHANGHAI - China Pharma Holdings, a generic drug provider in China, reported that its net income inched up by 6.2 percent to $4.3 million in the second quarter of 2009 compared with the same period of 2008
More Investment In China’s Health Care System Unveiled During NPC; Is It Time To Ask Who Will Benefit First And Most?
SHANGHAI - With the world economy in a downturn, the annual session of China's National People's Congress, one of the most important meetings in the country, is being held in Beijing